NCT01078597View on ClinicalTrials.gov

A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA

CompletedOBSERVATIONAL
Enrollment

35

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Rheumatoid Arthritis
Trial Locations (4)

Unknown

Site Reference ID/Investigator# 49402, Cork

Site Reference ID/Investigator# 49403, Cork

Site Reference ID/Investigator# 22307, Dublin

Site Reference ID/Investigator# 72114, Dublin

Sponsors

Collaborators (1)

JSS Medical Research Inc.
All Listed Sponsors
collaborator

JSS Medical Research Inc.

INDUSTRY

collaborator

Clinical Trial End-Point (CTEP) Ltd

UNKNOWN

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY